AbCellera Biologics(ABCL) - 2022 Q2 - Earnings Call Presentation

Financial Highlights - The company reported total revenue of $45.9 million in Q2 2022, driven by royalties from bebtelovimab [29] - The company experienced a net loss of $6.8 million, equivalent to $0.02 per share (basic and diluted) [37] Business Updates - The company maintains a strong cash position with substantial cash, cash equivalents, and marketable securities [8] - The company has cumulative programs under contract [8] - The company highlights the complexity and technology-intensive nature of the path from target identification to Investigational New Drug (IND) status [10] - The company aims to deliver value by accelerating drug development, innovating in previously inaccessible areas, and leveling the playing field for partners [11] Technology Development - The company is developing a T-cell engager platform, with data indicating a wide range of functional activities from its CD3 antibody panel [18] - The company's pre-partnered programs include a Pandemic Response Platform and a GPCRs & Ion Channels Platform [21] - The company's pandemic response technology led to two COVID-19 antibody treatments and treated over 2.5 million patients [22] Partnerships and Programs - The company has 38 discovery partners [27] - The company has 6 molecules in the clinic as of June 30, 2022, including bamlanivimab and bebtelovimab [28]